Drug Profile
Influenza trivalent vaccine intranasal - Advagene Biopharma
Alternative Names: Inactivated trivalent influenza vaccine; Inactivated trivalent seasonal influenza vaccine; Influenza vaccine intranasal - Advagene Biopharma; Nasal influenza vaccine - Advagene BioPharmaLatest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Advagene Biopharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 24 Nov 2023 Phase-II development is ongoing Taiwan
- 17 Mar 2021 No development reported - Phase-II for Influenza virus infections (Prevention) in Taiwan (Intranasal)
- 06 Oct 2017 Advagene plans a phase II trial for Influenza virus infection in Taiwan (Advagene BioPharma pipeline, October 2017)